The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 1, 2006, Pages 40-44

  McCollum, A David ^a   Wu, Bingyan ^d   Clark, Jeffrey W ^e   Kulke, Matthew H ^b,c   Enzinger, Peter C ^b,c   Ryan, David P ^e   Earle, Craig C ^b,c   Michelini, Ann ^b   Fuchs, Charles S ^b,c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Department of Biostatistics ^*  (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Capecitabine; Chemotherapy; Colorectal cancer; Thalidomide

Indexed keywords

CAPECITABINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; THALIDOMIDE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; MALE; METASTASIS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; SOMNOLENCE; VENOUS THROMBOEMBOLISM; COLORECTAL TUMOR; DISEASE COURSE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 33644852628     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000190456.83788.51     Document Type: Article

References (26)

1. Goldberg RM, Sargent D, Morton R, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
2. Tournigand C, Theirry A, Emmanuel A, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237.
3. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorecal cancer improves with the availability of fluorouracil- leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209-1214.
4. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
6. Saltz LB, Meropol NJ, Loehrer P, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-1208.
7. Rothenberg M, Oza A, Bigelow R, et al. Superiority of Oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol. 2003;21:2059-2069.
8. Hoff P, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282-2292.
9. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097-4106.
10. Hoff P, Pazdur R, Lassere Y, et al. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol. 2004;22:2078-2083.
11. Haslett PA, Klausner JD, Makonkawkeyoon S, et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses. 1999;15:1169-1179.
12. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-4085.
13. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997;64:971-978.
14. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.
15. Shinghal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
16. Marx G, McCowatt S, Boyle F, et al. Phase II study of thalidomide as an antiangiogenic agent in the treatment of recurrent glioblastoma multiforme. Proc Am Soc Clin Oncol. New Orleans, 2000;613a.
17. Patt Y, Hassan M, Lozano R, et al. Phase II trial of thalidomide for treatment of nonresectable hepatocellular carcinoma. Proc Am Soc Clin Oncol. New Orleans, 2000;1035a.
18. Fujii T, Tachibana M, Dhar DK, et al. Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice. Anticancer Res. 2003;23:2405-2411.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
20. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1959;53:457-481.
21. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) Study E3200. Proceedings Gastrointestinal Cancers Symposiom. Hollywood, 2005.
22. Saltz LB, Lenz HJ, Kindler H, et al. Randomized Phase II trial of cetuximab/bevacizumab/irinotecan versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer. Proceedings Gastrointestinal Cancers Symposium. Hollywood, 2005.
23. Gubanski M, Almerud A, Lidestahl A, et al. Capecitabine as third line therapy in patients with advanced colorectal cancer. ASCO Gastrointestinal Symposium. San Francisco, 2004.
24. Govindarajan R, Safar AM, Maddox A, et al. Irinotecan and thalidomide prolong disease free and overall survival in 5FU reftactory metastatic colorectal cancer. Proc Am Soc Clin Oncol. Chicago, 2003:249.
25. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352:1413-1418.
26. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352:1407-1412.